Kaleido is one of the world's smallest and lightest insulin patch pumps, with a low ecological footprint due to its reusable design

Kaleido是世界上最小，最轻的胰岛素贴片泵之一，由于其可重复使用的设计，生态足迹低

Paired with the Diabeloop DBLG1 control software and Dexcom G6 CGM sensor, it serves as a world class Hybrid Closed Loop Insulin dosing system, improving users' Time in Range glucose values by 16.7%1

与Diabeloop DBLG1控制软件和Dexcom G6 CGM传感器配合使用，成为世界级混合闭环胰岛素给药系统，使用时间范围内葡萄糖值提高了16.7%1

Kaleido can be worn as a patch on the body or carried in the pocket. DBLG1 requires only four parameters for setup after which it's self-learning

Kaleido可以作为身体上的贴片穿着或装在口袋里。DBLG1只需要四个参数即可设置，之后它就可以自我学习了

UTRECHT, Netherlands, Nov. 21, 2023 /PRNewswire/ -- ViCentra B.V., the company behind Kaleido, one of the world's smallest, lightest insulin patch pump systems for managing type 1 diabetes, is pleased to announce the launch of a Hybrid Closed Loop system for automated insulin delivery. This system delivers insulin by using the DBLG1 algorithm, which receives input from the Dexcom G6 Continuous Glucose Monitoring (CGM) sensor..

荷兰乌得勒支，2023年11月21日/PRNewswire/-世界上最小，最轻的用于管理1型糖尿病的胰岛素贴片泵系统之一-卡莱多背后的公司ViCentra B.V.很高兴宣布推出混合闭环系统，用于自动胰岛素输送。该系统通过使用DBLG1算法提供胰岛素，DBLG1算法接收来自Dexcom G6连续血糖监测（CGM）传感器的输入。。

It combines the convenience of the Kaleido insulin pump with two market-leading innovations designed by Diabeloop and Dexcom to create a Hybrid Closed Loop system for managing type 1 diabetes which is flexible, self-learning and easy to use.

它将Kaleido胰岛素泵的便利性与Diabeloop和Dexcom设计的两项市场领先创新相结合，创建了一个灵活，自学且易于使用的混合闭环系统，用于管理1型糖尿病。

Frans Cromme, Chief Executive Officer of ViCentra, said: 'We aim to deliver the best user experience as well as excellent clinical results with our Kaleido insulin pump and our partners. Kaleido with DBLG1 and Dexcom G6 improves users' Time in Range by 16.7%1, an achievement that should bring real benefits to people with type 1 diabetes.

ViCentra首席执行官Frans Cromme说：“我们的目标是与我们的Kaleido胰岛素泵和我们的合作伙伴提供最佳的用户体验和出色的临床效果。使用DBLG1和Dexcom G6的Kaleido将用户的时间提高了16.7%1，这一成就应该为1型糖尿病患者带来真正的益处。

We are proud to deliver this game changing technology via a beautiful and small device, as we feel people deserve this when they need to rely on a medical device 24/7.'.

我们很自豪通过一个美丽而小型的设备提供这种改变游戏规则的技术，因为我们觉得当人们需要全天候依赖医疗设备时，他们应该得到这一点。

Inge Van Boxelaer, endocrinologist at AZ St-Lucas Ghent hospital, remarked: 'I love seeing ViCentra trying to make these people's lives a little better. If I were a person with diabetes, I would be incredibly open to such a small, innovative and cheerfully coloured Kaleido insulin pump which is perfectly formed and discreet.'.

AZ St Lucas Ghent医院内分泌学家Inge Van Boxelaer说：“我喜欢看到ViCentra试图让这些人的生活变得更好。如果我是一个患有糖尿病的人，我将难以置信地打开这样一个小的，创新的，快乐的彩色Kaleido胰岛素泵，它是完美形成和谨慎的。

Nienke Rutgers, a person with Type 1 diabetes, commented: 'Kaleido gives me an undisturbed life and is flexible in all situations during the day. I can wear it directly on my body and I do not notice it. Being even less preoccupied with diabetes is great, I do not have to focus on the condition, and I can get on with daily activities.

1型糖尿病患者Nienke Rutgers评论说：“Kaleido给了我一个不受干扰的生活，白天在所有情况下都很灵活。我可以直接将它戴在身体上，我没有注意到它。更少关注糖尿病是伟大的，我不必关注病情，我可以继续进行日常活动。

It is super nice also that Kaleido comes with a well-known product like DBLG1.'.

Kaleido还推出了一款着名的产品，如DBLG1。

Kaleido users can wear their pump as a patch or place it in their pocket at their own discretion. The system comes with two durable pumps that are rechargeable, eliminating the need to dispose of the pump every 3 days as other patch pumps do. It is available in 10 bright colours and provides the ability to pause or take the pump off for intermittent breaks..

Kaleido用户可以将泵作为贴片佩戴，也可以自行决定放入口袋中。该系统配有两个可再充电的耐用泵，与其他补丁泵一样，无需每3天处理一次泵。它有10种明亮的颜色，可暂停或抽出泵以进行间歇性中断。。

Diabeloop's DBLG1 is a system deploying a well-known algorithm that is used by 10,000+ users2 in Europe already. The system draws on real-time glucose data, reducing hypoglycaemia by more than 50%3 and using personalised parameters and self-learning to adjust Kaleido's insulin delivery for an optimised management of type 1 diabetes.

Diabeloop的DBLG1是一个部署着名算法的系统，该算法已被欧洲10000多名用户2使用。该系统利用实时血糖数据，将低血糖降低50%以上3，并使用个性化参数和自我学习来调整Kaleido的胰岛素输送，以优化1型糖尿病的治疗。

DBLG1 algorithm considers the user's glucose levels provided by the Dexcom G6 Continuous Glucose Monitor (CGM) alongside inputs on meals and activities to determine the insulin delivery. Users and healthcare professionals have real-time access to their data insights via automated transfer to the cloud platform YourLoops..

DBLG1算法考虑由Dexcom G6连续血糖监测仪（CGM）提供的用户葡萄糖水平以及膳食和活动输入以确定胰岛素递送。用户和医疗保健专业人员可以通过自动传输到云平台YourLoops实时访问他们的数据见解。。

ViCentra is launching the Hybrid Closed Loop system in Germany, the Netherlands and France with its commercial partner Diabeloop. Roll-out to additional countries which include the UK and Italy is planned for 2024.

ViCentra正在与其商业合作伙伴Diabeloop在德国，荷兰和法国推出混合闭环系统。计划于2024年推广到包括英国和意大利在内的其他国家。

Stephane Majerus, Chief Executive Officer of Diabeloop, commented: 'We are proud to extend our partnership with ViCentra, home of Kaleido, offering people with type 1 diabetes a new level of options in the management of their diabetes. This alliance between Diabeloop's algorithm technology and the ViCentra pump aims to offer people with diabetes the benefits of the Kaleido design combined with our highly performing and proven algorithm.

Diabeloop首席执行官Stephane Majerus评论说：“我们很自豪地扩展与Kaleido之家ViCentra的合作关系，为1型糖尿病患者提供新的糖尿病治疗选择。Diabeloop算法技术与ViCentra泵之间的这种联盟旨在为糖尿病患者提供Kaleido设计的优势，并结合我们高性能和经过验证的算法。

Diabeloop's ultimate goal remains to make available the most advanced solutions to improve the quality of life of people with diabetes, enabling them to devote more time to their passions and daily lives.'.

Diabeloop的最终目标仍然是提供最先进的解决方案，以改善糖尿病患者的生活质量，使他们能够花更多的时间投入到他们的激情和日常生活中。

Notes to Editors

编辑注释

About ViCentraViCentra B.V., with headquarters in Utrecht, the Netherlands develops, manufactures and markets next generation insulin patch pumps and for insulin delivery for people with type 1 diabetes. The company's flagship product is the Kaleido insulin pump which is CE marked and commercially available in Europe.

关于ViCentraViCentra B.V.，总部位于乌得勒支，荷兰开发，制造和销售下一代胰岛素贴片泵，并为1型糖尿病患者提供胰岛素输送。该公司的旗舰产品是Kaleido胰岛素泵，该泵已在欧洲进行CE标记并在市场上销售。

It is one of the world's smallest, lightest insulin pump systems, waterproof, available in 10 colour combinations and is available both as a manual and a Hybrid Closed Loop System. ViCentra was founded in 2013 and is backed by INKEF Capital, EQT Life Sciences, Health Innovations, Invest-NL, Partners in Equity, and Kreos Capital.

它是世界上最小，最轻的胰岛素泵系统之一，防水，有10种颜色组合，可作为手动和混合闭环系统使用。ViCentra成立于2013年，得到INKEF Capital，EQT生命科学，Health Innovations，Invest NL，Partners in Equity和Kreos Capital的支持。

More information about ViCentra can be found at www.hellokaleido.com..

有关ViCentra的更多信息，请访问www.hellokaleido.com。。

About DBLG1 with Kaleido – Hybrid Closed Loop SystemWith a simple setup procedure using only four different parameters and no need for a fingerstick test*, the cutting-edge Hybrid Closed Loop System saves time for healthcare professionals by providing 24/7 insights with automatic data transfer sharing with care teams, linked to the cloud (YourLoops), providing infinite possibilities for its users.

关于带有Kaleido混合闭环系统的DBLG1通过仅使用四个不同参数且不需要指尖测试的简单设置程序*，尖端混合闭环系统通过提供全自动24/7见解为医疗保健专业人员节省时间与护理团队共享数据传输，连接到云（YourLoops），为用户提供无限的可能性。

The different tube lengths allow the user to wear the pump as a patch or place in the pocket and is available in a range of assorted colours, providing a pump which is personalized to each user. With a modular design, the Kaleido pump is also designed to be more sustainable, with two reusable pumps and a reusable handset.

不同的管长允许用户将泵作为贴片或放入口袋中，并且可以提供各种颜色，为每个用户提供个性化的泵。通过模块化设计，Kaleido泵的设计也更加可持续，有两个可重复使用的泵和一个可重复使用的手机。

Infusion sets and cartridges can be changed separately when it is convenient for the user, at least every 3 days..

当用户方便时，至少每3天可以单独更换输液器和药筒。。

About DiabeloopDiabeloop's mission: Making innovation accessible to people living with diabetes, improving clinical results while relieving them of their constant mental burden.

关于DiabeloopDiabeloop的使命：为糖尿病患者提供创新，改善临床结果，同时减轻他们不断的精神负担。

Created in 2015, Diabeloop offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden.  DBLG1 System, Diabeloop's Hybrid Closed Loop algorithm integrated in a dedicated handset, is a CE-marked medical device under MDR standards and distributed in Europe..

Diabeloop创建于2015年，提供基于AI的个性化解决方案，以改善糖尿病患者的临床结果，同时减轻他们不断的精神负担。DBLG1系统是集成在专用手机中的Diabeloop混合闭环算法，是MDR标准下的CE标记医疗设备，在欧洲分销。。

Today, Diabeloop gathers the personality, passion, and skills of talented individuals who work hard to improve the quality of life for every person living with diabetes. More information about Diabeloop can be found at www.diabeloop.com.

今天，Diabeloop收集了才华横溢的个人的个性，激情和技能，他们努力提高每个糖尿病患者的生活质量。有关Diabeloop的更多信息，请访问www.Diabeloop.com。

About DexCom, Inc.DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology.

关于DexCom，Inc.DexCom，Inc。通过创新的连续血糖监测（CGM）系统，使人们能够实时控制健康。总部设在加利福尼亚州圣地亚哥。，随着欧洲和亚洲/大洋洲部分地区的运营，Dexcom已成为糖尿病护理技术的领导者。

By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com..

通过听取用户，护理人员和提供者的需求，Dexcom致力于简化和改善全球糖尿病管理。有关Dexcom CGM的更多信息，请访问www.Dexcom.com。。

*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

*如果您的血糖警报和G6读数与症状或预期不符，请使用血糖仪做出糖尿病治疗决策。

1 Amadou, Coralie, Sylvia Franc, Pierre-Yves Benhamou, Sandrine Lablanche, Erik Huneker, Guillaume Charpentier, and Alfred Penfornis. 2021. 'Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-Up.' Diabetes Care 44(3):844–46.

1 Amadou，Coralie，Sylvia Franc，Pierre-Yves Benhamou，Sandrine Lablanche，Erik Huneker，Guillaume Charpentier和Alfred Penfornis。2021.“Diabeloop DBLG1闭环系统使1型糖尿病患者能够在没有严重不良事件的情况下显着改善现实生活中的血糖控制：6个月的随访。”糖尿病护理44（3）：844-46。

doi: 10.2337/dc20-1809..

二：10.2337/dc20-1809。。

2 English Portal - Diabeloop: interoperable self-learning diabetes management solutions (cea.fr)

2英语门户-Diabeloop：可互操作的自学糖尿病管理解决方案（cea.fr）

3 Benhamou, Pierre-Yves, Sylvia Franc, Yves Reznik, Charles Thivolet, Pauline Schaepelynck, Eric Renard, Bruno Guerci, Lucy Chaillous, Celine Lukas-Croisier, Nathalie Jeandidier, Helene Hanaire, Sophie Borot, Maeva Doron, Pierre Jallon, Ilham Xhaard, Vincent Melki, Laurent Meyer, Brigitte Delemer, Marie Guillouche, Laurene Schoumacker-Ley, Anne Farret, Denis Raccah, Sandrine Lablanche, Michael Joubert, Alfred Penfornis, and Guillaume Charpentier.

3 Benhamou，Pierre Yves，Sylvia Franc，Yves Reznik，Charles Thivolet，Pauline Schaepelynck，Eric Renard，Bruno Guerci，Lucy Chaillous，Celine Lukas Croisier，Nathalie Jeandidier，Helene Hanaire，Sophie Borot，Maeva Doron，Pierre Jallon，Ilham Xhaard，Vincent Melki，Laurent Meyer，Brigitte Delemer，Marie Guillouche，Laurene Schoumacker Ley，Anne Farret，Denis Raccah，Sandrine Lablanche，Michael Joubert，Alfred Penfornis和Guillaume Charpentier。

2019. 'Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes in Real-Life Conditions: A 12-Week Multicentre, Open-Label Randomised Controlled Crossover Trial.' The Lancet Digital Health 1(1):e17–25. doi: 10.1016/S2589-7500(19)30003-2..

2019.“在现实生活条件下成人1型糖尿病的闭环胰岛素输送：一项为期12周的多中心，开放标签随机对照交叉试验”柳叶刀数字健康1（1）：e17-25。doi:10.1016/S2589-7500（19）30003-2。。

SOURCE ViCentra

来源ViCentra